Clovis Oncology Inc. announced topline data from the confirmatory phase III ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival by investigator review in each of the three populations studied.
A study from the Austrian Breast & Colorectal Cancer Study Group indicates that women with metastasized breast cancer do not benefit from surgery performed prior to drug treatment. This could cause a paradigm shift in treatment of the disease.
Eisai Inc. announced results from the REFLECT study, a phase III trial evaluating lenvatinib (Lenvima), the company's multiple receptor tyrosine kinase inhibitor (including fibroblast growth factor receptors, for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. announced that data from the randomized phase III Alcanza clinical trial evaluating Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma was published in Lancet.
A meta-analysis of previously published cancer research showed no difference in five-year and 10-year survival rates between patients who underwent radical cystectomy and a bladder-preserving combined modality treatment plan.
Patients with advanced or inoperable Hepatocellular Carcinoma who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress 2017.
FDA granted regular approval to Keytruda (pembrolizumab) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
The NCI Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
New study findings link traveling to an academic medical center for surgical removal of pancreatic or thyroid cancer with higher quality surgical care for both cancers, and longer survival for patients with pancreatic cancer compared with patients who receive treatment at a hospital closer to home.
A study shows that the number of women in the United States living with distant metastatic breast cancer is growing. This is likely due to the aging of the US population and improvements in treatment.
